Guardant Health’s InfinityAI Platform Supports ENHERTU Approval in Japan

Key Facts

1Guardant Health's InfinityAI platform provided real-world evidence (RWE) that supported the approval of ENHERTU in Japan.

2ENHERTU was approved for patients with HER2-positive advanced or recurrent solid cancers.

3Daiichi Sankyo developed and commercialized ENHERTU in Japan.

Guardant Health announced that its InfinityAI platform provided critical real-world evidence (RWE) to support the regulatory approval of ENHERTU in Japan. Developed and commercialized by Daiichi Sankyo, ENHERTU is now approved for treating patients with HER2-positive advanced or recurrent solid tumors. This milestone highlights the growing importance of precision oncology data and AI-driven insights in securing regulatory clearances for complex therapies. The approval validates Guardant Health’s AI capabilities as a valuable tool for pharmaceutical partners during the clinical submission process. For Daiichi Sankyo, the expanded indication significantly broadens the addressable market for its flagship oncology treatment in the Japanese market. Investors view this development as a positive sign for the future adoption of AI-driven clinical evidence across the global biotech industry.